Candel Therapeutics Statistics
Total Valuation
CADL has a market cap or net worth of $984.03 million. The enterprise value is $831.98 million.
| Market Cap | 984.03M |
| Enterprise Value | 831.98M |
Important Dates
The last earnings date was Thursday, August 13, 2026, before market open.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CADL has 76.52 million shares outstanding. The number of shares has increased by 45.29% in one year.
| Current Share Class | 76.52M |
| Shares Outstanding | 76.52M |
| Shares Change (YoY) | +45.29% |
| Shares Change (QoQ) | +18.87% |
| Owned by Insiders (%) | 7.77% |
| Owned by Institutions (%) | 59.79% |
| Float | 60.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 396.79 |
| PB Ratio | 7.76 |
| P/TBV Ratio | 7.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.09, with a Debt / Equity ratio of 0.39.
| Current Ratio | 16.09 |
| Quick Ratio | 15.89 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.26 |
Financial Efficiency
Return on equity (ROE) is -81.84% and return on invested capital (ROIC) is -32.81%.
| Return on Equity (ROE) | -81.84% |
| Return on Assets (ROA) | -28.64% |
| Return on Invested Capital (ROIC) | -32.81% |
| Return on Capital Employed (ROCE) | -36.83% |
| Weighted Average Cost of Capital (WACC) | 1.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.61M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +116.13% in the last 52 weeks. The beta is -0.50, so CADL's price volatility has been lower than the market average.
| Beta (5Y) | -0.50 |
| 52-Week Price Change | +116.13% |
| 50-Day Moving Average | 10.17 |
| 200-Day Moving Average | 7.02 |
| Relative Strength Index (RSI) | 65.70 |
| Average Volume (20 Days) | 1,308,202 |
Short Selling Information
The latest short interest is 12.66 million, so 16.54% of the outstanding shares have been sold short.
| Short Interest | 12.66M |
| Short Previous Month | 12.96M |
| Short % of Shares Out | 16.54% |
| Short % of Float | 21.07% |
| Short Ratio (days to cover) | 9.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -71.98M |
| Pretax Income | -88.53M |
| Net Income | -88.53M |
| EBITDA | -71.30M |
| EBIT | -71.98M |
| Earnings Per Share (EPS) | -$1.44 |
Balance Sheet
The company has $201.57 million in cash and $49.52 million in debt, with a net cash position of $152.05 million or $1.99 per share.
| Cash & Cash Equivalents | 201.57M |
| Total Debt | 49.52M |
| Net Cash | 152.05M |
| Net Cash Per Share | $1.99 |
| Equity (Book Value) | 126.13M |
| Book Value Per Share | 1.66 |
| Working Capital | 191.47M |
Cash Flow
In the last 12 months, operating cash flow was -$56.02 million and capital expenditures -$1.30 million, giving a free cash flow of -$57.32 million.
| Operating Cash Flow | -56.02M |
| Capital Expenditures | -1.30M |
| Depreciation & Amortization | 678,000 |
| Net Borrowing | 41.21M |
| Free Cash Flow | -57.32M |
| FCF Per Share | -$0.75 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CADL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -45.29% |
| Shareholder Yield | -45.29% |
| Earnings Yield | -9.00% |
| FCF Yield | -5.83% |
Analyst Forecast
The average price target for CADL is $20.88, which is 62.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.88 |
| Price Target Difference | 62.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |